2-(4'-methylaminophenyl)benzothiazole: binds amyloid-beta fibrils; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9837643 |
| CHEMBL ID | 93334 |
| SCHEMBL ID | 493341 |
| MeSH ID | M0448209 |
| Synonym |
|---|
| CHEMBL93334 , |
| bta-1, >=98% (hplc), solid |
| NCGC00165760-01 |
| bta-1 |
| (4-benzothiazol-2-yl-phenyl)-methyl-amine |
| 4-(benzo[d]thiazol-2-yl)-n-methylaniline |
| bdbm50109052 |
| AKOS003383867 |
| 439858-28-3 |
| 4-(1,3-benzothiazol-2-yl)-n-methylaniline |
| 6X-7042 |
| SCHEMBL493341 |
| 2-(4'-methylaminophenyl)benzothiazole |
| DTXSID90431602 |
| [4-(1,3-benzothiazol-2-yl)phenyl]methylamine |
| doi:10.14272/fhjrkgxjbxpbga-uhfffaoysa-n.1 |
| 10.14272/FHJRKGXJBXPBGA-UHFFFAOYSA-N.1 |
| 921193-28-4 |
| bta-eg4 |
| CS-0323149 |
| HY-W278021 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 19.9526 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 39.8107 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 28.1838 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 18.3916 | 35.4813 | AID2107 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 35.4813 | 0.0366 | 19.6376 | 50.1187 | AID2112 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.2874 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Amyloid-beta precursor protein | Homo sapiens (human) | Ki | 0.0061 | 0.0001 | 0.0856 | 0.8900 | AID38663; AID445593 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID209521 | Percent injected dose per gram of compound to Swiss-Webster mice brain was measured after 2 min of intravenous injection | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. |
| AID38663 | Binding affinity for Amyloid beta 1-40 aggregates in competition with [N-methyl-3H] BTA-1. | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. |
| AID19837 | Apparent lipophilicity was determined | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. |
| AID24451 | Octanol-water partition at pH 7.4 | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. |
| AID445593 | Binding affinity to Beta amyloid aggregates in Alzheimer's disease patient brain by competitive binding assay | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. |
| AID230105 | Ratio of percent injected dose per gram of compound to Swiss-Webster mice brain after 2 min and 30 min of intravenous injection | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. |
| AID232143 | Ratio of 2-30 min mouse brain uptakes per g was determined | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. |
| AID533777 | Binding affinity to amyloid beta (1 to 40) | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22 | Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques. |
| AID209522 | Percent injected dose per gram of compound to Swiss-Webster mice brain was measured after 30 min of intravenous injection | 2003 | Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13 | Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. |
| AID112234 | Compound was tested in vivo for mouse brain uptake after 30 min; Mouse brain uptake per g | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. |
| AID32557 | In vitro binding using synthetic aggregated Abeta(1-40) fibrils | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. |
| AID112233 | Compound was tested in vivo for mouse brain uptake after 2 min; Mouse brain uptake per g | 2002 | Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3 | A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||